Abstract: The invention provides a stepping doser. The doser comprises a bearing component, a dosing catheter, wiring tubes, a threaded rod, a nut, a signal recorder and a connecting rod; wherein the middle socket of the threaded rod is sheathed with a nut, the lower end of the threaded rod contacts the lower inner wall of the bearing component, the upper end of the threaded rod penetrates the upper part of the bearing component, and the upper end of the threaded rod is provided with a driving structure; The bearing component is also provided with a limit stop for limiting the rotation of the nut so that when the threaded rod rotates, the nut can move up and down; when the nut moves up and down, the dosing catheter can move up and down. The dosing catheter can be stepped with this doser, allowing dosing in a larger area.

Abstract: The present disclosure provides a method and a storage medium for transmitting a message. The method includes: sending a current message transmission packet to an output device, the current message transmission packet including current message data and transmission progress information; obtaining an acknowledgement packet from the output device; and sending transmission progress information in the acknowledgement packet to a persistent storage system, such that the persistent storage system stores the transmission progress information in the acknowledgement packet as input progress information of the current message data.

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.

Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: The present disclosure provides a method and a storage medium for transmitting a message. The method includes: sending a current message transmission packet to an output device, the current message transmission packet including current message data and transmission progress information; obtaining an acknowledgement packet from the output device; and sending transmission progress information in the acknowledgement packet to a persistent storage system, such that the persistent storage system stores the transmission progress information in the acknowledgement packet as input progress information of the current message data.

Abstract: Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention provides novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.

Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to a series of analogs of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogs of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like.

Abstract: The present invention relates to a series of analogues of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogues of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like.